Breast Cancer Invasive clinical trials

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

Imlunestrant and abemaciclib for early ER+ breast cancer

This trial tests whether adding two targeted drugs, imlunestrant and abemaciclib, to your usual hormone therapy can lower the chance of your breast cancer coming back. It is for people with early-stage ER+ breast cancer who have no signs of cancer on scans but have tiny amounts of tumor DNA in their blood (called ctDNA).

Identifying breast cancer through a blood test

This study tests a blood test designed to help find breast cancer. It may help detect the disease earlier, which could make treatment more effective.

Hormone therapy with or without chemo for early breast cancer

This trial tests whether skipping chemotherapy and using only hormone therapy with a drug called ribociclib works as well as chemotherapy followed by hormone therapy with ribociclib for certain early breast cancers that have a low risk of coming back.

Neratinib before surgery for HER2-mutated invasive lobular breast cancer

This Phase 2 trial tests neratinib given before surgery to treat stage I–III invasive lobular breast cancer that has a specific HER2 mutation and is hormone-receptor positive. It may help shrink the tumor and improve control of cancer before and after surgery.

Low-dose Capecitabine for High-risk Early Breast Cancer

This study tests whether a low-dose chemotherapy pill called capecitabine can help prevent breast cancer from coming back in patients whose cancer shows signs of remaining disease (called MRD) despite standard treatment. The trial focuses on hormone-receptor-positive, HER2-negative breast cancers.

Avoiding armpit lymph node removal in breast cancer

This trial tests whether it is safe to skip removing lymph nodes from the armpit when cancer has spread there but has been found by ultrasound. If you have breast cancer that has spread to armpit lymph nodes and are not getting chemotherapy before surgery, this study may be an option.

Exercise for heart health after breast cancer

This study compares two types of exercise programs for women who have completed breast cancer treatment. It aims to see which type of training helps improve heart health and fitness.

Radiation and immunotherapy before surgery for HR+/HER2- breast cancer

This trial is testing a new treatment approach for patients with a certain type of breast cancer (HR+/HER2-). It combines radiation therapy with chemotherapy and an immunotherapy drug before the patient's main surgery, to see if it can shrink or eliminate the tumor more effectively.

Evorpacept with trastuzumab and chemo for HER2-positive breast cancer

This study tests an experimental drug called evorpacept when given with trastuzumab and chemotherapy for people with HER2-positive breast cancer that has spread. The goal is to see if this combination can shrink tumors or slow down the cancer.

Personalized tamoxifen dosing for breast cancer

This trial tests whether adjusting the dose of tamoxifen based on your body's processing can improve treatment for hormone-sensitive breast cancer. It aims to find the best dose for you while keeping side effects manageable.

Predicting outcomes for newly diagnosed metastatic breast cancer

This study uses information from women with newly diagnosed breast cancer that has spread (metastatic) to create a tool that helps predict how the disease may progress. By looking at your medical records, they hope to improve care and help future patients.

Time-restricted eating during breast cancer chemotherapy

This study is testing whether time-restricted eating (confining all meals to a specific window each day) can improve the response to chemotherapy in women with newly diagnosed breast cancer. Participants will follow this eating pattern for 16 weeks while receiving their standard chemotherapy, and the researchers will monitor how the tumor shrinks.

Testing less radiation to the inner breast area

This trial studies whether some patients with early-stage breast cancer can safely skip a specific part of radiation to the inner chest (called internal mammary irradiation). It may reduce radiation side effects while still aiming to prevent the cancer from coming back.

New blood test model to check lymph node status in breast cancer

This study uses a blood test and imaging to predict whether breast cancer has spread to underarm lymph nodes, helping guide surgery. It may reduce unnecessary lymph node removal.

Tested extra radiation to the tumor area in HER2-positive breast cancer

This study follows people with HER2-positive invasive breast cancer to see how adding radiation to the tumor bed may affect outcomes. It may be most relevant if you are scheduled for breast radiation and have not had radiation to the same side before.

Elacestrant for ER-positive, HER2-negative breast cancer with ctDNA relapse

This trial tests whether elacestrant can help stop or delay breast cancer coming back in people whose blood test shows “ctDNA relapse” after early breast cancer treatment. It’s meant for hormone receptor–positive, HER2-negative breast cancer patients who are already taking hormone (endocrine) therapy and have no visible spread on scans.

Sacituzumab Govitecan for newly diagnosed TNBC

This trial tests a drug called sacituzumab govitecan for people with newly diagnosed triple-negative breast cancer (TNBC) that hasn't been treated yet. The drug targets cancer cells directly to try to stop them from growing.

Robotic-assisted nipple-sparing mastectomy trial

This trial tests a robotic-assisted surgery technique for women who need a mastectomy but can keep their skin and nipple. It aims to improve outcomes for breast cancer patients and those at high risk.

BL-M07D1 vs T-DM1 for HER2-positive breast cancer after neoadjuvant therapy

This trial tests whether a new drug called BL-M07D1 works better than an existing drug, T-DM1, for people with HER2-positive breast cancer who still have cancer cells after initial treatment (neoadjuvant therapy). The goal is to prevent the cancer from coming back.

Chemo plus immunotherapy for early HR+/HER2- breast cancer

This trial tests adding an immunotherapy drug (serplulimab) to standard chemotherapy for early-stage HR+/HER2- breast cancer. The goal is to see if the combination works better than chemo alone before surgery.

Endoscopic vs standard breast-conserving surgery after chemo

This study compares two types of breast-conserving surgery for women who have already had chemotherapy before their operation. It aims to see if using a tiny camera (endoscope) leads to equally good long-term results as standard breast-conserving surgery.

Pyrotinib and trastuzumab with chemo for HER2+ advanced breast cancer

This trial tests a combination of two targeted medicines (pyrotinib and trastuzumab) with chemotherapy to treat HER2-positive advanced breast cancer that has returned or spread after stopping trastuzumab.

Lower-dose chemo for older women with HER2-negative breast cancer

This trial tests whether a lower dose of two chemotherapy drugs (docetaxel and cyclophosphamide) works well for women 65 and older with early-stage HER2-negative breast cancer. The goal is to maintain effectiveness while reducing side effects in this group.